A silent shift is reshaping how we manage chronic illness and mental health, and it’s happening in the palm of our hands.
From anxiety to diabetes, digital therapeutics (DTx), clinically backed software, and app-based treatments are taking off. A recent market outlook projects that the global DTx industry will leap from USD 2.83 billion today to a staggering USD 19.8 billion by 2035, as patients, providers, and health systems alike embrace software-based care with clinical rigor.
In place of traditonal medications, or alongside prescribed, these apps are changing into FDA-cleared therapies, and no longer seen as just supplemental wellness tools. Under the growing burden of lifestyle diseases and mental health conditions, the healthcare system has seen a boom in both innovation and user demand.
Unlike traditional health apps, digital therapies go through extensive clinical testing and regulatory authorization. They’re designed to target specific health outcomes whether that’s reducing depressive episodes, improving sleep quality, or stabilizing blood sugar levels.
Dozens of new platforms are providing personalized treatments for PTSD, ADHD, chronic pain, and obesity. These digital protocols often use cognitive behavioral therapy (CBT), guided journaling, biofeedback, or gamified behavior change modules to deliver care in a daily, personalized format.
And the best part? Patients can access it all from home.
Healthcare providers are increasingly open to prescribing these solutions, especially for patients who face barriers to in-person therapy or ongoing care. In many cases, digital therapeutics are proving not just convenient but effective in reducing symptoms and improving adherence when compared to conventional methods.
As the DTx space grows, so too does the need for thoughtful digital marketing that educates without overwhelming.
Several companies are rolling out short, animated storytelling videos to explain how their platforms work. These clips follow real or simulated user journeys chronicling the transformation from daily struggle to stability, with a clear emphasis on clinical support and personal empowerment.
To keep users engaged and on track, strengthen therapeutic routines while offering motivation, check-ins, and milestone rewards, the in-app push campaigns are also being used.
On the B2B front, digital therapeutics providers are increasingly turning to LinkedIn ads and clinician-focused webinars to reach doctors, psychiatrists, and health insurers. These platforms highlight scientific validation, compliance features, and how digital care can be integrated into hybrid or remote-first practices.
Some are even using AI-driven CRM tools to segment audiences, tailoring messages for patients, caregivers, or institutional buyers separately.
Through professional and formal press release services, many DTx innovators are choosing to make announcements as competition increases. Using press release distribution that targets healthcare media, regulatory watchers, and digital health influencers, companies are forming their tools not just as products, but clinically validated interventions.
Releases often carry headlines like “Launching Our Clinically Validated Digital Therapeutic for Generalized Anxiety Disorder” and include trial outcomes, quotes from medical officers or trial investigators, and early adoption projections. In doing so, these announcements position the company as a thought leader while signaling transparency and evidence to skeptical audiences.
One such example came earlier this month, when a digital health startup launched its new CBT-based program for insomnia. The accompanying release was picked up by both MedTech Dive and Healthline, following targeted outreach and precise keyword strategy, proof that a well-timed press release still has the power to spark national coverage when executed right.
At its core, the rise of digital therapeutics speaks to a larger shift: healthcare is moving toward accessibility, personalization, and prevention.
In a world where mental health backlogs can stretch for months, and managing chronic illness often requires daily commitment, DTx offers an elegant, data-driven bridge. Patients feel more in control. Providers get measurable results. And the healthcare ecosystem gets a scalable solution.
As we move into the next decade of medicine, these platforms won’t just be “nice to have,” they’ll be essential. And for startups, clinicians, and public health stakeholders alike, the message is clear: the time to build and believe in digital therapeutics is now.
Daniel 
DCAuthorityLinks